SMYD5

Across TCGA pan-cancer cohorts, SMYD5 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of SMYD5’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SMYD5 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SMYD5 is over-expressed in tumor, although a few such as PDAC and COAD show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where SMYD5 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SMYD5 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	+0.420	<.001	11	view →
LUAD	Male	All	+0.280	<.001	9	view →
LSCC	Male	II,III,IV	+0.253	<.001	7	view →
PDAC	All	All	−0.160	.010	4	view →
COAD	Male	All	−0.212	.014	1	view →
HNSC	Male	IV	+0.177	.023	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

SMYD5–CCRCC

Open the CCRCC breakdown →